source
- Novo outlines $23 billion 2035 revenue target, but investors react with a 7% share dropNovo’s chief executive used the recent Capital Markets Day to lay out a long‑term growth plan that targets $23 billion in annual sales by 2035. The strategy emphasizes expanding beyond its flagship…
- Telix to acquire German radioisotope maker ITM in deal valued up to $2.35 billionTelix Pharmaceuticals announced it will purchase ITM Isotope Technologies Munich SE, a German producer of medical radioisotopes, for an upfront payment of $1.65 billion. The transaction could rise…